Program
Tolvaptan
Also written as “OPC-41061”, “tolvaptan” and “Tolvaptan MR”.
Its studies are mostly in Polycystic Kidney, Autosomal Dominant · Hyponatremia · Heart Failure · Fibrosis · Kidney Failure, Chronic, led by 2 companies.
Drug pageTolvaptan: every studyAll 89 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsukaits history only | 541 open or running | phase 4since Sep 15, 2011 | Aug 13, 2002 | Dec 28, 2028phase 3 · NCT04782258 |
| Jiangsu HengRui Medicine | 10 open or running | phase 3since Jan 5, 2012 | Jan 5, 2012 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Jiangsu HengRui Medicine only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 5, 2012First study: phase 3 study in HyponatremiaFirst studyNCT01507727 · 240 enrolled · China
TargetBeta
“An orally bioavailable, selective, arginine vasopressin receptor 2 (V2, AVPR2) antagonist that can be used to treat hyponatremia”NCIt, by rule
“Vasopressin V2 receptor antagonist”ChEMBL 37, by rule
Studies
The one study Jiangsu HengRui Medicine leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01507727Hyponatremia · China | 3 | UNKNOWN | Sep 2012 | 240 |
How it is read
Names in the registry
- “Tolvaptan”, 30 entries
- “OPC-41061”, 12 entries
- “tolvaptan”, 6 entries
- “Tolvaptan MR”, 5 entries
- “OPC-41061(Tolvaptan)”, 3 entries
Conditions, from the studies’ own filings
- Polycystic Kidney, Autosomal Dominant, 12 studies
- Hyponatremia, 11 studies
- Heart Failure, 8 studies
- Fibrosis, 4 studies
- Kidney Failure, Chronic, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.